Inozyme Pharma INZY 深 滬
等待開盤 08-05 09:30:00 美东时间
4.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 4.00
- 總市值 2.58亿
- 52周最高 6.24
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.721
- 委 比 0.00%
- 總股本 6456.18万
- 歷史最高 31.65
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.721
- 每 手 1
- 風險率 0.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Inozyme Pharma Requests Nasdaq Delisting Post-Acquisition
An announcement from Inozyme Pharma ( ($INZY) ) is now available. Inozyme Pharm...
07-01 21:48
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
Inozyme Pharma has postponed its 2025 Annual Meeting due to the pending acquisition by BioMarin Pharmaceutical Inc. If the acquisition is completed, the meeting will not be held. If not, the Board may reschedule it with a new record date. Inozyme, a biopharmaceutical company, focuses on bone health and blood vessel function, developing INZ-701 for ENPP1 Deficiency and other conditions.
06-20 21:00
Inozyme Pharma Reports Increased Loss Amid Strategic Focus
Inozyme Pharma, Inc. ( ($INZY) ) has released its Q1 earnings. Here is a breakd...
06-10 11:51
Inozyme Pharma Approves Executive Bonuses Amid Merger
Inozyme Pharma ( ($INZY) ) has issued an update. On May 16, 2025, Inozyme Pharm...
06-02 19:58
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
BioMarin Agrees To Acquire Inozyme For $4.00/Shr In All-Cash Transaction For Total Consideration Of About $270M
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 DeficiencyFirst Pivotal Data Readout in Children Expected in Early 2026 with
05-16 19:33
快讯 | Inozyme Pharma Inc - Biomarin重申2025年财务指导
Inozyme Pharma Inc - Biomarin Reaffirms 2025 Financial Guidance
05-16 19:31
快讯 | Biomarin通过收购Inozyme Pharma加强酶治疗业务
Biomarin Strengthens Enzyme Therapy Business With Acquisition of Inozyme Pharma
05-16 19:30
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Childre...
05-16 19:30
